Please assess the completion status of the following clinical trial:

Trial Title: A Study of CC-99712, a BCMA Antibody-Drug Conjugate, in Participants With Relapsed and Refractory Multiple Myeloma

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Participants must satisfy the following criteria to be enrolled in the study:~Inclusion~* Participant is ≥ 18 years of age at the time of signing the ICF.~* Participant has a history of multiple myeloma (MM) with relapsed and/or refractory disease~* Participant must have measurable disease.~* Participant has an Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 or 1.~Exclusion Criteria~* Participant has symptomatic central nervous system involvement of MM.~* Participant had a prior autologous stem cell transplant ≤ 3 months prior to starting CC-99712.~* Participant had a prior allogeneic stem cell transplant with either standard or reduced intensity conditioning ≤ 6 months prior to starting CC-99712 or is on systemic immunosuppression for graft-versus host disease.~* Subject is a pregnant or lactating female.~* Subject has known human immunodeficiency virus (HIV) infection.~* Subject has active hepatitis B or C (HBV/HCV) infection.~Other protocol-defined inclusion/exclusion criteria apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm 1 (CC-99712 monotherapy) (Type: EXPERIMENTAL): CC-99712 will be administered via intravenous (IV) infusion.
- Arm 2 (CC-99712 and BMS-986405 combination) (Type: EXPERIMENTAL): CC-99712 will be administered via IV infusion. BMS-986405 will be administered orally.

Based on this trial design, predict the completion outcome and termination type (if applicable).